Humana Inc outlook and business model as health insurance demand stays robust
Humana Inc operates as a major US health insurer with a focus on Medicare Advantage and Medicaid, leveraging an aging population and government-funded programs. Its business model relies on efficient management of medical costs, risk adjustments, and adaptability to evolving health policies. The company also invests in health services capabilities and technology to manage care, control costs, and maintain a competitive edge.
UnitedHealth says most home-health diagnoses were supported in 2025
UnitedHealth announced that an audit by FTI Consulting found nearly 97% of diagnoses made by its HouseCalls home-health unit in 2025 were supported by patient medical records. This comes after scrutiny from lawmakers and the Department of Health and Human Services regarding unsupported diagnoses impacting Medicare Advantage payments. The company acknowledges room for improvement in documentation practices.
Cantor Fitzgerald raises Humana stock price target on Medicaid data
Cantor Fitzgerald has increased its price target for Humana Inc. (NYSE:HUM) shares to $300 from $264, while maintaining a Neutral rating. This adjustment was made due to positive partial second-quarter 2026 Medicaid enrollment data, suggesting Humana is trending positively in enrollment growth. Despite the adjusted price target, Humana's current stock price of $392.86 is significantly higher, near its 52-week high, following a 68% gain over the past year.
July 2026 Regulatory & Legislative Update
This July 2026 update details regulatory and legislative changes impacting several key areas. It covers developments in gender identity discrimination under the ACA, FLSA overtime exemption standards, the ERISA status of "Trump Accounts," and recent antitrust settlements for Blue Cross Blue Shield. The update also includes information on PCORI fee reporting, Massachusetts MCC standards for 2027, and mid-year increases in Paid Family and Medical Leave benefits in certain states.
CMS proposes expanded authority to revoke Medicare privileges
CMS is proposing to expand its authority to revoke Medicare provider privileges as part of an effort to crack down on healthcare fraud, waste, and abuse. The proposed rule would allow CMS to remove providers for additional reasons, including operating in areas with an "excessive" number of providers, convictions related to sexual assault or financial misconduct, or issues with owners' licenses in other states. These changes, part of the Calendar Year 2027 Home Health Prospective Payment System Proposed Rule, aim to save taxpayers an estimated $82 million annually while also updating home health payments with a 2.4% increase.
UnitedHealth Group underscores its role in U.S. health coverage as investors watch long term growth
UnitedHealth Group is a major player in the U.S. healthcare sector, integrating insurance and health services. The company's diversified model and involvement in public programs like Medicare and Medicaid are key factors for investors evaluating its long-term growth prospects. Its ability to balance growth with cost management in a highly regulated industry is also a significant consideration.
UnitedHealth Group highlights diversified health benefits and services portfolio as investors track long-term growth drivers
UnitedHealth Group Incorporated continues to emphasize its diversified portfolio of health benefits and services. The company's dual structure as both an insurer and a services provider, combining commercial, Medicare, and Medicaid plans with pharmacy benefits and data analytics, is a key feature. Investors are closely monitoring membership trends, medical cost management, and the company's role in the broader U.S. healthcare system.
CVS Health: The Surprising Healthcare Outlier (NYSE:CVS)
CVS Health has distinguished itself through strong management and strategic execution, outperforming peers despite industry challenges. The company reported a significant Q1 beat, anticipates margin expansion in 2026, and projects low double-digit investor returns. While its Health Services and Insurance segments are expected to grow, the retail segment will see gradual decline offset by improved margins, leading to a reiterated 'Buy' rating.
Cantor Fitzgerald reiterates Neutral on Humana stock at $264
Cantor Fitzgerald has reiterated a Neutral rating on Humana Inc. (NYSE:HUM) with a $264 price target, despite the stock currently trading significantly higher. The firm noted Humana's strategic shift towards increased Medicaid exposure, highlighting recent enrollment changes in Kentucky and Louisiana, and mentioned the company's recent contract win in Illinois and sale of its stake in Gentiva. InvestingPro analysis suggests Humana is undervalued and has "GOOD" financial health.
Cantor Fitzgerald reiterates Neutral on Humana stock at $264 By Investing.com
Cantor Fitzgerald maintained a Neutral rating and a $264 price target for Humana (NYSE:HUM), despite the stock currently trading significantly higher at $396.75 and near its 52-week high. The firm highlighted Humana’s increased Medicaid exposure and its performance in Kentucky and Louisiana, where the company gained enrollment from a competitor's contract termination. InvestingPro analysis suggests Humana is undervalued with "GOOD" financial health.
Ambetter health plans from Centene Corp. - a key Obamacare product for US families
Ambetter health plans by Centene Corp. are a major product line on the Affordable Care Act (ACA) marketplaces, providing essential health benefits to millions of US families. The plans offer tiered options (bronze, silver, gold), digital tools, and focus on affordability for individuals and families without employer-sponsored coverage. Ambetter's presence across many states and its integration with ACA subsidies make it a significant player in the national health insurance landscape, affecting both consumers and Centene's financial performance.
Humana Inc. (HUM) Stock Analysis: Navigating Market Dynamics with a 23.50% Revenue Growth in Healthcare Plans
Humana Inc. (NYSE: HUM) is navigating dynamic market conditions with a strong presence in the healthcare plans sector, boasting a $47.63 billion market capitalization and 23.50% revenue growth driven by its Insurance and CenterWell divisions. Despite mixed market sentiment and stock volatility, analysts anticipate continued earnings growth, supported by a healthy free cash flow and a modest dividend yield. While technical indicators suggest a bullish phase, the discrepancy between the current price and target prices emphasizes the need for thorough analysis of market conditions for investors.
Molina Healthcare outlines its managed care strategy as a US Medicaid specialist
Molina Healthcare specializes in government-sponsored health plans, primarily focusing on Medicaid, Medicare, and Affordable Care Act (ACA) marketplaces. The company operates as a managed care organization, contracting with state agencies to provide health benefits to vulnerable populations, emphasizing care coordination and cost control. Its business model, which includes a diversified portfolio of government-related health plans, is attractive to investors interested in publicly funded healthcare.
Jim Cramer Says He Bets “The Gains in CVS Will Be Long-Lasting”
Jim Cramer expressed positive sentiment towards CVS Health Corporation, predicting that its recent gains will be long-lasting. He highlighted the company's strong performance in its latest quarter, including an earnings beat and a raised full-year forecast, which led to a 7.7% stock increase and a three-year high. Cramer also sees value in other health insurers like UnitedHealth and Humana.
HUM - Humana Inc Latest SEC Filings
This article provides the latest SEC filing information and comprehensive financial data for Humana Inc. (HUM). It details various financial metrics such as market cap, income, sales, P/E ratios, dividend information, and performance indicators, alongside insider ownership and institutional transactions. The data reflects the company's financial health and stock performance as of July 2, 2024.
CVS Health Corp. highlights evolving role in U.S. healthcare. Investors weigh integrated care strategy
CVS Health Corp. is expanding its integrated healthcare model, combining pharmacy, insurance, and clinical services to achieve long-term stability in the evolving U.S. healthcare landscape. The company's diversified approach, spanning retail pharmacies, pharmacy benefit management, and health insurance, aims to create a comprehensive care ecosystem. Investors are evaluating how effectively this integrated structure can translate into resilient earnings and improved patient outcomes through coordinated care.
Strs Ohio Has $55.25 Million Stock Position in CVS Health Corporation $CVS
Strs Ohio has reduced its holdings in CVS Health Corporation by 13.4% in the first quarter, now owning 769,277 shares valued at approximately $55.25 million. Despite this reduction, Wall Street analysts maintain a "Moderate Buy" rating for CVS, with a consensus target price of $101.28. The company recently reported strong quarterly results, surpassing earnings and revenue estimates, and raised its full-year 2026 EPS guidance.
Fideuram Intesa Sanpaolo Private Banking S.P.A. Acquires 32,077 Shares of CVS Health Corporation $CVS
Fideuram Intesa Sanpaolo Private Banking S.P.A. increased its stake in CVS Health Corporation by 28.6% in the first quarter, purchasing an additional 32,077 shares. Institutional investors collectively own 80.66% of CVS Health's stock, though several insider sales by EVP Tilak Mandadi and Director Larry Robbins were also reported. Analysts generally forecast growth for CVS Health, with a consensus "Moderate Buy" rating and an average target price of $101.28.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Humana Inc. (HUM) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Humana Inc. (NYSE: HUM) for alleged corporate wrongdoing. The firm is encouraging shareholders who purchased Humana securities before June 27, 2022, and still hold them, to join the investigation. Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, seeking to recover investor capital and ensure corporate accountability.
Humana (HUM) director Hilzinger granted 233 RSUs, holds 19,448 shares
Humana Inc. director Kurt J. Hilzinger was granted 233 Restricted Stock Units (RSUs) on June 30, 2026, as a compensation-related equity award, with a reference price of $392.32 per share. Following this transaction, he directly holds 19,448 shares of Humana common stock and 16,534 RSUs. These RSUs and deferred stock units, which arise from annual director fees, cash fee conversions, and dividend reinvestments, are payable in Humana common stock upon his resignation from the board.
Humana Inc (HUM) Stock Down 3.1% but Still Overvalued -- GF Scor
Humana Inc (HUM) shares recently dropped 3.1% to $396.75, yet the stock is still considered overvalued according to its GF Value™ estimate. Despite a strong GF Score™ of 86/100, driven by growth and momentum, the company's financial strength and valuation raise concerns for investors. There has been no insider trading activity in the last three months, suggesting a stable internal outlook on the company's direction.
Elevance Health sues over Medicare Advantage star ratings
Elevance Health has filed a lawsuit against the Centers for Medicare and Medicaid Services (CMS) regarding the recalculation of the 2026 Medicare Advantage star ratings. The CMS plans to redo these star ratings for all insurance providers. The article highlights other related news in politics and regulation, including HHS freezing New York's Medicaid fraud unit funds and CMS proposing changes to hospital outpatient pay and 340B cuts.
Humana Inc. stock underperforms Thursday when compared to competitors
Humana Inc. (HUM) stock underperformed on Thursday, dropping 3.09% to $396.75. This occurred during a mixed trading session where the S&P 500 Index remained largely unchanged and the Dow Jones Industrial Average rose. The stock's decline ended a six-day winning streak.
PCRX's Exparel Wins Separate Reimbursement From UnitedHealthcare
Pacira BioSciences (PCRX) announced that UnitedHealthcare will now provide separate reimbursement for its non-opioid pain medicine, Exparel, in outpatient settings. This decision is expected to improve patient access and support the use of non-opioid pain management after surgery, following similar policies from other major insurers and expanded Medicare coverage. Exparel is Pacira's primary growth driver, with ongoing initiatives to expand its indications and geographic reach.
Top National Health Plan Extends Agreement for Mental Health and Expands Dario Partnership into Cardiometabolic Care, Demonstrating Successful Multi-Condition Growth Strategy
DarioHealth Corp. announced that a top national health insurer has expanded its partnership to include Dario's hypertension solution, following the success of its behavioral health offering. This expansion is expected to approximately triple Dario's revenue opportunity with this customer and validates its multi-condition strategy. It marks the third health plan customer to broaden its deployment beyond an initial condition, reinforcing Dario's ability to grow within its existing customer base by delivering integrated care across various chronic conditions.
Humana Foundation awards $12M to combat loneliness among seniors
The Humana Foundation has announced a $12 million initiative to combat loneliness, depression, and social isolation among older adults. A significant portion of this funding, $1.45 million, is earmarked for programs specifically in Louisville. This effort highlights the foundation's commitment to supporting the well-being of seniors.
USS Investment Management Ltd Has $16.68 Million Stock Holdings in CVS Health Corporation $CVS
USS Investment Management Ltd increased its stake in CVS Health Corporation by 5.4% in the first quarter, now holding 232,198 shares valued at approximately $16.68 million. CVS Health reported strong Q1 earnings with EPS of $2.57 against estimates of $2.21 and revenues of $100.43 billion, leading to raised FY 2026 guidance. Wall Street maintains a "Moderate Buy" consensus rating with an average price target of $101.28, reflecting positive sentiment.
Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®
Pacira BioSciences announced that UnitedHealthcare will now provide separate reimbursement for EXPAREL® (bupivacaine liposome injectable suspension) in outpatient settings, including hospital outpatient departments and ambulatory surgery centers. This decision expands access to non-opioid postsurgical pain management for approximately 40 million UnitedHealthcare members. With this, a total of about 150 million covered lives nationwide now have access to separate reimbursement for EXPAREL, reducing financial barriers to non-opioid pain management.
Humana Inc. stock outperforms competitors on strong trading day
Humana Inc. (HUM) shares rose 3.07% to $409.42 on Wednesday, marking its sixth consecutive day of gains, despite a negative trading session for the broader stock market. The S&P 500 Index (SPX) fell 0.22%, and the Dow Jones Industrial Average (DJIA) fell 0.03%, highlighting Humana's strong individual performance against market trends.
DarioHealth (DRIO) Expands Reach via Beluga Health Deal
DarioHealth (DRIO) has expanded its reach through a collaboration with Beluga Health, integrating its AI-driven multi-condition platform with Beluga's clinical network across all 50 states. This partnership enables DarioHealth to provide provider-backed care for chronic conditions like diabetes, hypertension, and behavioral health, appealing to health plans seeking scalable and clinically effective solutions. The move comes as the digital health sector experiences rapid growth, with analysts setting price targets between US$25 and US$28 for DRIO.
Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®
Pacira BioSciences announced that UnitedHealthcare will now provide separate reimbursement for EXPAREL® (bupivacaine liposome injectable suspension) across various outpatient settings. This development expands patient access to non-opioid postsurgical pain management for approximately 40 million UnitedHealthcare members. With this addition, EXPAREL now has separate reimbursement access for about 150 million covered lives nationwide, reducing financial barriers for patients seeking non-opioid pain solutions after surgery.
Cantor Fitzgerald reiterates Surgery Partners stock rating at Overweight
Cantor Fitzgerald has reiterated its Overweight rating on Surgery Partners (NASDAQ:SGRY) with a price target of $18.00, despite the stock being slightly overvalued according to InvestingPro data. The firm's analysis indicates less optimistic views on outpatient pricing step-up than consensus. Investors are focusing on the recovery of pressure facilities and the upcoming 2026 Investor Day, which is expected to include portfolio updates. Analysts also predict the company will achieve profitability this year with an EPS forecast of $0.43.
US firms score roles on the $69bn CVS Health Aetna merger
McDermott Will & Schulte, a global law firm, advised CVS Health Corp. on its $69 billion acquisition of insurer Aetna Inc., a deal expected to significantly impact the US healthcare sector. The acquisition was one of the largest M&A transactions in 2017. Several partners from McDermott's offices in Washington, DC, Chicago, and Dallas were involved in this major deal.
Humana, Centene lead healthcare rally in Q2 over Medicare Advantage optimism
The healthcare sector rallied in Q2, primarily driven by optimism surrounding proposed increases in Medicare Advantage payments. This led to significant outperformance by managed care companies like Humana and Centene, despite the sector lagging the broader markets due to concerns over drug pricing and policy uncertainty. The sustainability of this rally and the impact of other healthcare themes remain key risks.
Pictet Asset Management Holding SA Sells 277,329 Shares of CVS Health Corporation $CVS
Pictet Asset Management Holding SA reduced its stake in CVS Health Corporation by 33.4% in the first quarter, selling 277,329 shares and leaving it with 553,318 shares valued at approximately $39.7 million. While CVS Health has shown positive operating momentum and hit a 52-week high, it also faces regulatory pressure, including a probe in Florida regarding alleged pharmacy steering. Despite some insider selling, analysts generally maintain an optimistic outlook with a "Moderate Buy" rating.
The Humana Foundation Deepens Investment in Emotional Health, Announcing Over $12 Million in New Grants
The Humana Foundation has announced over $12.2 million in new grants for 2026, focusing on emotional well-being and combating loneliness, depression, and social isolation among seniors and veterans. These investments support 13 nonprofit organizations and five university research teams through community-based programs and innovative research. The grants aim to scale proven interventions, integrate behavioral health services, foster intergenerational connections, and advance research in emotional health and nutrition to create healthier, more joyful lives for older adults.
DarioHealth adds former Humana compliance chief to board
DarioHealth Corp. (NASDAQ:DRIO) has appointed Sean O’Reilly, former Senior Vice President and Chief Compliance Officer at Humana, to its Advisory Board. This strategic move aims to bolster DarioHealth's channel partner-led growth strategy, leveraging O'Reilly's extensive experience in healthcare compliance and risk management, despite the company facing a recent 24% revenue decline. InvestingPro analysis suggests the stock is currently undervalued, with the company maintaining a healthy current ratio, and it recently reported positive Q1 2026 earnings with revenue growth and reduced operating expenses.
DarioHealth Adds Former Humana Compliance Chief Sean O’Reilly to Advisory Board
DarioHealth Corp. (NASDAQ: DRIO) has appointed Sean O’Reilly, former Humana Chief Compliance Officer, to its Advisory Board. This strategic move aims to leverage O'Reilly's extensive experience in healthcare compliance and regulatory oversight as DarioHealth expands its partnerships and the adoption of its AI-enabled platform for behavioral and chronic condition management. The appointment signals DarioHealth's focus on strengthening governance and payer relationships in a complex regulatory environment.
Humana Inc. stock outperforms competitors on strong trading day
Humana Inc. (HUM) shares rose 2.14% to $397.22 on a strong trading day, outperforming competitors as the S&P 500 and Dow Jones Industrial Average also saw gains. This marks the fifth consecutive day of increases for Humana's stock.
The Humana Foundation Deepens Investment in Emotional Health, Announcing Over $12 Million in New Grants
The Humana Foundation has announced over $12 million in new grants for 2026, focusing on emotional health and combating senior loneliness. These grants will support 13 nonprofit organizations and five university research teams across the U.S., scaling community-based programs and funding innovative research. The initiatives aim to foster social engagement, improve well-being for older adults, and address depression and social isolation among seniors and veterans.
Humana Foundation puts $12.2M into ending senior loneliness
The Humana Foundation has committed over $12.2 million in its first slate of 2026 grants to combat loneliness, depression, and social isolation among seniors and veterans. These grants will support 13 nonprofit organizations and five university research teams across multiple states, focusing on programs that foster social engagement, integrate behavioral health services, and advance research in emotional well-being and nutrition. The initiative aims to leverage community-based interventions and academic partnerships to create healthier, more joyful lives for older adults.
Plus Therapeutics to rebrand as Cerenome, change ticker to CNSY
Plus Therapeutics (NASDAQ:PSTV) will rebrand as Cerenome and change its ticker symbol to CNSY, starting August 3, 2026. The company, which specializes in central nervous system cancers, currently trades at $4.29 with a market capitalization of $29.7 million, despite a 66.5% year-to-date decline. This change comes as the company expands commercial payer coverage for its CNSide CSF Tumor Cell Enumeration assay and progresses its therapeutic programs.
Morgan Stanley raises UnitedHealth stock price target on utilization
Morgan Stanley has raised its price target for UnitedHealth Group (NYSE:UNH) to $468 from $453, maintaining an Overweight rating, citing favorable utilization trends and strong Optum Health execution. The firm expects above-consensus second-quarter earnings, set to be reported on July 16, 2026, marking the start of the managed care earnings season. UnitedHealth has also consistently increased its dividend for 16 consecutive years.
DarioHealth taps ex-Humana compliance chief for advisory board
DarioHealth (NASDAQ: DRIO) has appointed Sean O'Reilly, former Senior Vice President and Chief Compliance Officer at Humana, to its Advisory Board. This strategic move aims to enhance DarioHealth's compliance, regulatory, and payer expertise as it expands its AI-enabled digital health platform and channel partner-led growth with health plans, employers, and providers. O'Reilly's extensive background in healthcare compliance, risk management, and leveraging advanced data analytics and AI aligns with DarioHealth's focus on delivering measurable healthcare outcomes.
Dario Appoints Former Humana Chief Compliance Officer Sean O'Reilly to Advisory Board to Support Strategic Growth and Healthcare Partnerships
DarioHealth Corp. has appointed Sean O'Reilly, former Humana Chief Compliance Officer, to its Advisory Board to bolster strategic growth and healthcare partnerships. O'Reilly's extensive experience in healthcare compliance, risk management, and regulatory oversight, particularly with advanced data analytics and AI, aligns with Dario's focus on expanding relationships across the healthcare ecosystem. His expertise will help accelerate the adoption of Dario's AI-powered behavioral health and chronic multi-condition management platform within payer, provider, and employer markets.
Centene Corp. consensus picture on Wall Street, shares trade on the NYSE
Centene Corp. opens Tuesday with a steady analyst consensus on Wall Street, focusing on earnings expectations, valuation, and positioning among U.S. health insurance peers. The company, a U.S. managed-care and Medicaid specialist, is covered by major research houses like Goldman Sachs and JPMorgan. Analysts monitor metrics such as revenue growth, operating margins, and price-to-earnings multiples against competitors like UnitedHealth Group.
Dario Appoints Former Humana Chief Compliance Officer Sean O'Reilly to Advisory Board to Support Strategic Growth and Healthcare Partnerships
DarioHealth Corp. has appointed Sean O'Reilly, former Humana Chief Compliance Officer, to its Advisory Board. O'Reilly's extensive experience in healthcare compliance, risk management, and regulatory oversight is expected to bolster Dario's expansion with health plans, employers, and providers. His expertise in data analytics and AI for value-based care aligns with Dario's strategic focus on AI-enabled digital health solutions.
How payers, drugmakers can collaborate to drive more outcomes-based contracts
The article discusses the growing need for collaboration between payers and drug manufacturers to manage rising drug costs and promote value-based care. Cigna Group's Brian Evanko and EMD Serono's Miguel Fernández Alcalde highlighted their successful partnership in reducing fertility treatment costs as an example. They advocate for expanded outcomes-based pricing models, especially for high-cost therapies, stressing the importance of involving all stakeholders to balance innovation with affordability.
SCHD ETF: Why this 'anti-AI' fund is beating the S&P 500 and Nasdaq 100 indices
The Schwab US Dividend Equity ETF (SCHD) has demonstrated strong performance and significant inflows this year, outperforming major indices like the S&P 500 and Nasdaq 100, despite limited exposure to the AI sector. The fund's success is attributed to its concentration in traditional industries like healthcare and consumer staples, with top holdings like UnitedHealth Group and Merck experiencing substantial growth. This positioning makes SCHD a potential hedge against an AI market slowdown, and technical analysis suggests continued upward momentum.
Humana Inc. stock outperforms competitors on strong trading day
Humana Inc. (HUM) shares rose 1.32% to $388.90 on Monday, outperforming the broader market. This gain contributed to the stock's fourth consecutive day of increases, as the S&P 500 Index also saw a rise of 1.18%. The Dow Jones Industrial Average similarly advanced by 0.59% during the strong trading session.
